Spero.jpg
Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform
May 23, 2018 08:00 ET | Spero Therapeutics, Inc.
SPR741 Phase 1b Drug-Drug Interaction Study and SPR206 IND-enabling Studies Provide Support for Further Clinical Development Phase 1b data demonstrates pharmacokinetic compatibility and...
Spero.jpg
Spero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline Update
May 10, 2018 16:05 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May
May 01, 2018 09:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Highlights SPR741 Phase 1 and Preclinical Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases
April 16, 2018 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology
April 12, 2018 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 12, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Fourth Quarter and Full Year 2017 Operating Results and Provides Pipeline Update
April 02, 2018 16:10 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 02, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics to Present at Upcoming Investor Conferences
March 22, 2018 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics to Present at March Investor Conferences
March 01, 2018 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Announces Appointment of David P. Southwell to its Board of Directors
February 01, 2018 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer
January 04, 2018 07:30 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...